Key result
Candesartan linked to ~74% lower risk of early subclinical cardiotoxicity in doxorubicin-treated breast cancer patients.
Why the study?
There was no proven primary preventive strategy for doxorubicin-induced subclinical cardiotoxicity, particularly among patients without cardiovascular risk.
Does prophylactic candesartan or carvedilol prevent doxorubicin-induced subclinical cardiotoxicity in breast cancer patients without baseline cardiovascular risk?
Population
195 breast cancer patients without a CV risk scheduled for doxorubicin chemotherapy
Comparison
Candesartan 4 mg q.d. vs carvedilol 3.125 mg q.d. vs controls
Design
Partially randomized comparative study with non-randomized control group
Follow-up
At least 12 months
Authors
Loading...
May support candesartan to lower early cardiotoxicity risk; leaves open need for randomized confirmation.
Does prophylactic candesartan or carvedilol prevent doxorubicin-induced subclinical cardiotoxicity in breast cancer patients without baseline cardiovascular risk?
Low-dose candesartan may be effective in preventing early subclinical cardiotoxicity and LVEF decline in breast cancer patients receiving doxorubicin who lack baseline cardiovascular risk.
Lee et al. (2021) studied this question. Candesartan significantly reduced the incidence of early subclinical cardiotoxicity (4.9% vs. 18.6%, p = 0.022) in breast cancer patients treated with doxorubicin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: